These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 8769172)

  • 1. Delayed use of OKT3 for severe acute tubular necrosis in renal transplantation.
    VanderWerf BA
    Transplant Proc; 1996 Aug; 28(4):2115-6. PubMed ID: 8769172
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
    Kitabayashi K; Munn SR; Sterioff S
    Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
    Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
    Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunosuppression for recipients of kidneys from non-heart-beating donors: comparison of triple therapy and OKT3 regimens.
    Kehinde EO; Wheatley T; Feehally J; Nicholson ML; Veitch PS; Bell PR
    Transplant Proc; 1996 Jun; 28(3):1338-9. PubMed ID: 8658684
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
    Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
    Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
    [No Abstract]   [Full Text] [Related]  

  • 6. Does acute tubular necrosis affect renal transplant outcome? The impact of rejection episodes.
    Troppmann C; Almond PS; Payne WD; Dunn DL; Gores PF; Gruessner RW; Sutherland DE; Matas AJ; Najarian JS
    Transplant Proc; 1993 Feb; 25(1 Pt 2):905. PubMed ID: 8442263
    [No Abstract]   [Full Text] [Related]  

  • 7. OKT3 rescue therapy for 63 refractory rejections in 405 renal allografts.
    Uchida K; Namii Y; Tominaga Y; Haba T; Tanaka H; Ichimori T; Uemura O; Morozumi K; Hayashi S; Yokoyama J; Takagi H
    Transplant Proc; 1996 Jun; 28(3):1358-9. PubMed ID: 8658693
    [No Abstract]   [Full Text] [Related]  

  • 8. Combined high and low dosing of OKT3 for treatment of rejection episodes in renal transplants.
    Schweizer RT; Bartus S; Hull D; Perdrizet G; Roper L
    Transplant Proc; 1994 Dec; 26(6):3141. PubMed ID: 7998094
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of steroid resistant acute rejection after renal transplantation.
    Oh CK; Kim YS; Kim MS; Kim SI; Park K
    Transplant Proc; 1996 Jun; 28(3):1453-4. PubMed ID: 8658737
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term efficacy of OKT3 for steroid-resistant acute rejection in renal transplant patients.
    Kumano K; Irie A; Mashimo S; Endo T; Koshiba K
    Transplant Proc; 1996 Jun; 28(3):1354-5. PubMed ID: 8658691
    [No Abstract]   [Full Text] [Related]  

  • 11. OKT3 treatment for steroid-resistant acute rejection in kidney transplantation.
    Sevmis S; Emiroglu R; Karakayali F; Yagmurdur MC; Dalgic A; Moray G; Haberal M
    Transplant Proc; 2005 Sep; 37(7):3016-8. PubMed ID: 16213290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [OKT3 treatment of refractory renal allograft rejection].
    Xu J; Ma J; Bai X
    Zhonghua Wai Ke Za Zhi; 1997 Apr; 35(4):223-5. PubMed ID: 10374543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of OKT3 in steroid-resistant rejections following cadaveric kidney transplantation.
    Rosenkranz B; Niebel W; Albrecht K; Wagner K; Philipp T; Eigler FW
    Transpl Int; 1992; 5 Suppl 1():S112-3. PubMed ID: 14621750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal transplant artery thrombosis following treatment of allograft rejection with monoclonal anti-CD3 antibodies (OKT3).
    Noël C; Hazzan M; Coppin MC; Pruvot FR; Bridoux F; Lelièvre G
    Transplant Proc; 1995 Aug; 27(4):2438-9. PubMed ID: 7652870
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of cytomegalovirus infections with gancyclovir during OKT3 administration.
    Haberal M; Velidedoğlu E; Arslan G; Bilgin N; Büyükpamukçu N; Karamehmetoğlu M
    Transplant Proc; 1995 Oct; 27(5):2707. PubMed ID: 7482883
    [No Abstract]   [Full Text] [Related]  

  • 16. Proliferation rate of cells in the interstitial infiltrate in acute kidney allograft rejection.
    Olsen S; Hansen HE
    Transplant Proc; 1996 Feb; 28(1):502-3. PubMed ID: 8644329
    [No Abstract]   [Full Text] [Related]  

  • 17. Pediatric renal transplantation in a single center from Brazil.
    Abbud-Filho M; Ramalho H; Barberato JB; Silva ML; Yamazaki W; Salgueiro MC; Zerati-Fo M; D'Avila CL; Bezas AG
    Transplant Proc; 1995 Apr; 27(2):1834. PubMed ID: 7725526
    [No Abstract]   [Full Text] [Related]  

  • 18. Conversion from cyclosporine to tacrolimus in renal allograft recipients with delayed graft function from severe acute tubular necrosis.
    Jang HJ; Kim SC; Han DJ
    Transplant Proc; 2000 Nov; 32(7):1714-5. PubMed ID: 11119904
    [No Abstract]   [Full Text] [Related]  

  • 19. Correlation between Banff classification, acute renal rejection scores, and reversal of rejection.
    Gaber LW; Moore LW; Alloway RR; Flax S; Gaber AO
    Transplant Proc; 1995 Feb; 27(1):1019. PubMed ID: 7878784
    [No Abstract]   [Full Text] [Related]  

  • 20. Delayed graft function is associated with an increased incidence of occult rejection and results in poorer graft survival.
    Howard RJ; Pfaff WW; Brunson ME; Ramos EL; Peterson JC; Croker BP; Scornik JC; Parris CJ; Fennell RS
    Transplant Proc; 1993 Feb; 25(1 Pt 2):884. PubMed ID: 8442256
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.